Evercore ISI raised the firm’s price target on Waters to $355 from $335 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz
- Illumina upgraded, Fiserv initiated: Wall Street’s top analyst calls
- Wells Fargo starts tools and diagnostics group with positive bias
- Waters initiated with an Overweight at Wells Fargo
- Waters Corporation Welcomes New Board Member Heather Knight